株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

EpiCast Report:膀胱癌の疫学予測

EpiCast Report: Bladder Cancer - Epidemiology Forecast to 2022

発行 GlobalData 商品コード 290456
出版日 ページ情報 英文 37 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
EpiCast Report:膀胱癌の疫学予測 EpiCast Report: Bladder Cancer - Epidemiology Forecast to 2022
出版日: 2013年11月30日 ページ情報: 英文 37 Pages
概要

膀胱癌の世界における発生数は、毎年1200万件を超え、癌の中でも9番目に多い癌であると推定されています。主要6カ国(米国、フランス、ドイツ、イタリア、スペイン、英国)での発生数は2012年の16万3000件から2022年には19万9000件に達すると予測されており、5年間の患者数は年平均成長率2.22%で増加するものと予測されています。

当レポートは、WHO,IARC,NCIなどが発行している国別データに基づき、世界の主要6ヶ国における膀胱癌について、年齢、性別、病期別の有病率について予測を行っており、危険因子の概要と世界の動向、疫学予測、疫学レポート、疾患動向の分析を提供して、概略以下の構成でお届けいたします。

第1章 目次

第2章 イントロダクション

第3章 疫学

  • 疾患の背景
  • 危険因子と併存疾患
    • 喫煙はもっとも重大な危険因子
    • 男性膀胱癌患者の25%は、業務における芳香族アミンへの暴露によるもの
  • 世界の動向
    • 発生件数、死亡率、5年間の発生率
    • 相対生存率
    • 障害調整生存年数(DALY)、損失生存年数(YLL)
  • 予測手法
    • 利用した情報源
    • 利用しなかった情報源
    • 予測の前提条件と手法
  • 膀胱癌の疫学予測
    • 膀胱版の発生数
    • 発生数:年齢別
    • 発生数:性別
    • 発生率:年齢標準化
    • 発生数:診断ステージ別
    • 5年間の患者数
  • 議論
    • 疫学予測に関する考察
    • 分析の限界
    • 分析の強み

第4章 付録

図表

目次
Product Code: GDHCER042

With more than 12 million new cases occurring worldwide each year, bladder cancer is estimated to be the ninth most common cancer, and the thirteenth most numerous cause of death from cancer (Parkin, 2008; Ploeg et al., 2009). The major risk factors for bladder cancer are exposure to smoking and occupational risk factors such as exposure to aromatic amines. These risk factors are more prevalent among men, which makes the disease the seventh most common cancer in men, whereas it is the seventeenth most common cancer in women (Ploeg et al., 2009). The majority of bladder cancer cases are among older individuals with the median age at diagnosis being 73 years; because of this, the comorbidities associated with bladder cancer are similar to conditions typically occurring in older age and therefore, are not specific to bladder cancer (Prout et al., 2005).

By 2022, GlobalData epidemiologists forecast that the 6MM are expected to have 199,691 incident cases of bladder cancer, representing a 22.2% increase from the number of incident cases in 2012 (163,380 incident cases). In 2012, the 6MM had 575,251 five-year prevalent cases of bladder cancer and GlobalData epidemiologists forecast that by 2022, this number will grow to 703,227 five-year prevalent cases at an Annual Growth Rate (AGR) of 2.22%.

This forecast is supported by at least 10 years of historical data obtained from country-specific studies published by the World Health Organization's (WHO) International Agency for Research on Cancer (IARC), the National Cancer Institute's (NCI) Surveillance, Epidemiology, and End Results (SEER) Program, and the European Cancer Registry's fourth database registry (EUROCARE-4). The IARC's Cancer Incidence in Five Continents (CI-5) Plus data are the gold standard for country-level comparative analysis and was used to provide detailed case segmentation for each country by age and sex. Another major strength of this analysis is that GlobalData epidemiologists were able to forecast incident cases of bladder cancer in the 6MM by age, sex, and stage at diagnosis. Furthermore, the forecast methodology was also consistent across all markets, thereby allowing for a meaningful global comparison.

Scope

  • The Bladder Cancer EpiCast Report provides an overview of the risk factors and global trends of bladder cancer in the 6MM (US, France, Germany, Italy, Spain, and UK). It includes a 10-year epidemiological forecast for the incident cases of bladder cancer segmented by sex, age (in five-year age groups beginning at 15 years and ending at 75 years and older), and cancer stage at diagnosis (in situ, local, regional, distant, and unstaged), in addition to five-year prevalent cases in these markets.
  • The bladder cancer epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global bladder cancer market.
  • Quantify patient populations in the global bladder cancer market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for bladder cancer therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Upcoming Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
    • 3.2.1. Smoking is the most significant risk factor for bladder cancer
    • 3.2.2. Up to 25% of male bladder cancer cases are due to occupational exposure to aromatic amines
  • 3.3. Global Trends
    • 3.3.1. Incidence, Mortality, and Five-Year Prevalence
    • 3.3.2. Relative Survival
    • 3.3.3. Disability-Adjusted Life Years (DALYs) and Years of Life Lost (YLLs)
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods
  • 3.5. Epidemiological Forecast for Bladder Cancer (2012-2022)
    • 3.5.1. Incident Cases of Bladder Cancer
    • 3.5.2. Age-Specific Incident Cases of Bladder Cancer
    • 3.5.3. Sex-Specific Incident Cases of Bladder Cancer
    • 3.5.4. Age-Standardized Incidence Rates of Bladder Cancer
    • 3.5.5. Incident Cases of Bladder Cancer by Stage at Diagnosis
    • 3.5.6. Five-Year Prevalent Cases of Bladder Cancer
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Epidemiology and Health Policy
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Bladder Cancer Risk Factors 9
  • Table 2: 6MM, GLOBOCAN Incidence, Five-Year Prevalence, and Mortality of Bladder Cancer, Ages ≥15 Years, Men and Women, 2008 12
  • Table 3: 6MM, Relative Survival of Bladder Cancer (%), Men and Women 13
  • Table 4: 6MM, GLOBOCAN Disability-Adjusted Life Years (DALYs) and Years of Life Lost (YLLs) Due to Bladder Cancer, Men and Women, N, 2008 13
  • Table 5: 6MM, Sources of Bladder Cancer Incidence Data 14
  • Table 6: 6MM, Incident Cases of Bladder Cancer, Ages ≥15 Years, Men and Women, N, Select Years 2012-2022 19
  • Table 7: 6MM, Age-Specific Incident Cases of Bladder Cancer, Ages ≥15 Years, Men and Women, N (Row %), 2012 21
  • Table 8: 6MM, Sex-Specific Incident Cases of Bladder Cancer, Ages ≥15 Years, Men and Women, N (Row %), 2012 22
  • Table 9: 6MM, Incident Cases of Bladder Cancer by Stage at Diagnosis, Ages ≥15 Years, Men and Women, N (Row %), 2012 25
  • Table 10: 6MM, Five-Year Prevalent Cases of Bladder Cancer, Ages ≥15 Years, Men and Women, N, Select Years 2012-2022 26

List of Figures

  • Figure 1: 6MM, Incidence Rates of Bladder Cancer, Ages ≥15 Years, Men, Rate per 100,000 Population, 1993-2002 11
  • Figure 2: 6MM, Incidence Rates of Bladder Cancer, Ages ≥15 Years, Women, Rate per 100,000 Population, 1993-2002 12
  • Figure 3: 6MM, Incident Cases of Bladder Cancer, Ages ≥15 Years, Men and Women, N, Select Years 2012-2022 20
  • Figure 4: 6MM, Age-Specific Incident Cases of Bladder Cancer, Ages ≥15 Years, Men and Women, N, 2012 21
  • Figure 5: 6MM, Sex-Specific Incident Cases of Bladder Cancer, Ages ≥15 Years, Men and Women, N, 2012 23
  • Figure 6: 6MM, Age-Standardized Bladder Cancer Incidence, Ages ≥15 Years, Men and Women, Cases per 100,000 Population, 2012 24
  • Figure 7: 6MM, Incident Cases of Bladder Cancer by Stage at Diagnosis, Ages ≥15 Years, Men and Women, N, 2012 25
  • Figure 8: 6MM, Five-Year Prevalent Cases of Bladder Cancer, Ages ≥15 Years, Men and Women, N, 2012-2022 27
Back to Top